Xcout IntelSign inSubscribe

HitGen Inc.

688222BiotechChina

HitGen Inc. is a biopharmaceutical and contract research company that provides drug discovery services and technologies to the global pharmaceutical and biotechnology industry. It specializes in DNA-encoded library (DEL) technology, fragment-based drug discovery, structure-based drug design, and oligonucleotide-based therapeutics to discover novel small molecules and therapeutics for global clients and internal pipelines.

Subscribe to see HitGen Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

HitGen Inc. at a glance

HitGen Inc. is a biotech company headquartered in China. Xcout tracks 1 named person at HitGen Inc., including SUIBO LI (董事).

Industry
Biotech
Headquarters
China
Ticker
688222

HitGen Inc. leadership

  • SUIBO LI董事

HitGen Inc. competitors

A few of HitGen Inc.'s closest competitors — see the full list of competitors and alternatives →

VIVA BIOTECH01873 · BiotechShanghai, China
69% matchPublic

Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.

Market cap$396.6M
Employees2,169
VIVA BIOTECH competitors & alternatives →

Get HitGen Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

HitGen Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on HitGen Inc. in Xcout Intel

  • 1 named person with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →